253 related articles for article (PubMed ID: 24756371)
1. New strategies in ewing sarcoma: lost in translation?
Arnaldez FI; Helman LJ
Clin Cancer Res; 2014 Jun; 20(12):3050-6. PubMed ID: 24756371
[TBL] [Abstract][Full Text] [Related]
2. Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway.
van Maldegem AM; Bovée JV; Peterse EF; Hogendoorn PC; Gelderblom H
Eur J Cancer; 2016 Jan; 53():171-80. PubMed ID: 26765686
[TBL] [Abstract][Full Text] [Related]
3. Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma.
Vormoor B; Curtin NJ
Curr Opin Oncol; 2014 Jul; 26(4):428-33. PubMed ID: 24840521
[TBL] [Abstract][Full Text] [Related]
4. Prospects and challenges for the development of new therapies for Ewing sarcoma.
Grohar PJ; Helman LJ
Pharmacol Ther; 2013 Feb; 137(2):216-24. PubMed ID: 23085431
[TBL] [Abstract][Full Text] [Related]
5. Investigational therapies for Ewing sarcoma: a search without a clear finding.
Vornicova O; Bar-Sela G
Expert Opin Investig Drugs; 2016 Jun; 25(6):679-86. PubMed ID: 26988130
[TBL] [Abstract][Full Text] [Related]
6. Targeting the tumor microenvironment of Ewing sarcoma.
Morales E; Olson M; Iglesias F; Luetkens T; Atanackovic D
Immunotherapy; 2021 Dec; 13(17):1439-1451. PubMed ID: 34670399
[TBL] [Abstract][Full Text] [Related]
7. Ewing's sarcoma: overcoming the therapeutic plateau.
Subbiah V; Kurzrock R
Discov Med; 2012 Jun; 13(73):405-15. PubMed ID: 22742646
[TBL] [Abstract][Full Text] [Related]
8. Ewing sarcoma: investigational mono- and combination therapies in clinical trials.
Gartrell J; Rodriguez-Galindo C
Expert Opin Investig Drugs; 2021 Jun; 30(6):653-663. PubMed ID: 33870845
[TBL] [Abstract][Full Text] [Related]
9. The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.
Kailayangiri S; Altvater B; Meltzer J; Pscherer S; Luecke A; Dierkes C; Titze U; Leuchte K; Landmeier S; Hotfilder M; Dirksen U; Hardes J; Gosheger G; Juergens H; Rossig C
Br J Cancer; 2012 Mar; 106(6):1123-33. PubMed ID: 22374462
[TBL] [Abstract][Full Text] [Related]
10. Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging.
Liebsch L; Kailayangiri S; Beck L; Altvater B; Koch R; Dierkes C; Hotfilder M; Nagelmann N; Faber C; Kooijman H; Ring J; Vieth V; Rossig C
Br J Cancer; 2013 Aug; 109(3):658-66. PubMed ID: 23839490
[TBL] [Abstract][Full Text] [Related]
11. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
[TBL] [Abstract][Full Text] [Related]
12. Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma.
Omer N; Nicholls W; Ruegg B; Souza-Fonseca-Guimaraes F; Rossi GR
Front Immunol; 2021; 12():791206. PubMed ID: 34804076
[TBL] [Abstract][Full Text] [Related]
13. VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma.
Englisch A; Altvater B; Kailayangiri S; Hartmann W; Rossig C
Pediatr Blood Cancer; 2020 Oct; 67(10):e28313. PubMed ID: 32729251
[TBL] [Abstract][Full Text] [Related]
14. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.
Lamhamedi-Cherradi SE; Menegaz BA; Ramamoorthy V; Vishwamitra D; Wang Y; Maywald RL; Buford AS; Fokt I; Skora S; Wang J; Naing A; Lazar AJ; Rohren EM; Daw NC; Subbiah V; Benjamin RS; Ratan R; Priebe W; Mikos AG; Amin HM; Ludwig JA
J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27576731
[TBL] [Abstract][Full Text] [Related]
15. Experimental therapies and clinical trials in bone sarcoma.
Chugh R
J Natl Compr Canc Netw; 2010 Jun; 8(6):715-25. PubMed ID: 20581301
[TBL] [Abstract][Full Text] [Related]
16. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
17. Systematic review of phase-I/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research.
Felix A; Berlanga P; Toulmonde M; Landman-Parker J; Dumont S; Vassal G; Le Deley MC; Gaspar N
Cancer Med; 2021 Mar; 10(5):1589-1604. PubMed ID: 33452711
[TBL] [Abstract][Full Text] [Related]
18. Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force.
Bailey K; Cost C; Davis I; Glade-Bender J; Grohar P; Houghton P; Isakoff M; Stewart E; Laack N; Yustein J; Reed D; Janeway K; Gorlick R; Lessnick S; DuBois S; Hingorani P
F1000Res; 2019; 8():. PubMed ID: 31031965
[TBL] [Abstract][Full Text] [Related]
19. Emerging therapies in Ewing sarcoma.
Strauss SJ; Berlanga P; McCabe MG
Curr Opin Oncol; 2024 Jul; 36(4):297-304. PubMed ID: 38775200
[TBL] [Abstract][Full Text] [Related]
20. Ewing Sarcoma, an Update on Molecular Pathology with Therapeutic Implications.
de Alava E
Surg Pathol Clin; 2017 Sep; 10(3):575-585. PubMed ID: 28797503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]